Nebivolol, a new beta-blocker for the management of essential hypertension;Pharma clinics le médicament du mois le nébivolol (Nobiten®)

Revue Medicale de Liege

Volumn 56, Issue 11, 2001, Pages 788-791

  Scheen, A J ^a  

^a CHU SART TILMAN   (Belgium)

Author keywords

Arterial hypertension; Beta 1 selectivity; Beta blocker; Nebivolol; Nitric oxide

Indexed keywords

BETA 1 ADRENERGIC RECEPTOR; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CYTOCHROME P450 2D6; HYDROCHLOROTHIAZIDE; NEBIVOLOL; NEW DRUG; NITRIC OXIDE; NOBITEN;

ANTIHYPERTENSIVE ACTIVITY; ARTICLE; DRUG MECHANISM; DRUG METABOLISM; DRUG POTENTIATION; DRUG STRUCTURE; DRUG TOLERANCE; ESSENTIAL HYPERTENSION; GENETIC POLYMORPHISM; HEMODYNAMICS; HUMAN; MEMBRANE STABILIZATION; VASODILATATION;

ANTIHYPERTENSIVE AGENTS; BENZOPYRANS; CYTOCHROME P-450 CYP2D6; DRUG THERAPY, COMBINATION; ETHANOLAMINES; HUMANS; HYPERTENSION; LIVER;

EID: 17944394257     PISSN: 00353663     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (15)

1. Les bêa-bloquants
2. Hypertension 2000. Des directives ȧ la médecine basée sur des évidences scientifiques
3. Effect of beta-blockade on mortality among high-risk and low-risk patients after myocardial infarction
4. Diagnostic et traitement de la décompensation cardiaque
5. Increased survival with beta-blockers: Importance of ancillary properties
6. Do beta-blockers really increase peripheral vascular resistance? Review of the literature and new observations under basal conditions
7. Pharmacology of nebivolol
8. Nebivolol in the management of essential hypertension. A review
9. Nebivolol vasodilates human forearm vasculature: Evidence for an L-arginine/NO-dependent mechanism
10. Nitric oxide mediated venodilator effects of nebivolol
11. Pharmacological properties of nebivolol in man
12. The antihypertensive and hemodynamic effects of nebivolol
13. Exercise tolerance with nebivolol and atenolol
14. Treatment of ambulatory hypertensives with nebivolol or hydrochlorothiazide alone and in combination. A randomized, double-blind, placebo-controlled, factorial-design trial
15. Clinical pharmacokinetics of nebivolol: A review